Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
squamous cell carcinoma
Biotech
Replimune shares halve as skin cancer drug fails phase 2
Replimune’s skin cancer med is an “active agent” according to CEO Philip Astley-Sparke, but it didn’t achieve the main goals of a phase 2 trial.
Annalee Armstrong
Dec 5, 2023 10:35am
Checkpoint on track to add indications for cancer drug approval
Jun 16, 2022 3:49pm
Gilead joins Big Pharma peers at Dragonfly's pond in $300M deal
May 2, 2022 9:50am
Idera's only asset flounders as biotech, AbbVie end enrollment
Dec 15, 2021 11:15am
Cedilla adds $25M to series B to test two cancer drugs in trials
Oct 25, 2021 6:30am
New cancer targets unveiled in map of protein interactions
Oct 1, 2021 9:00am
